• About
    • Awards
    • History
    • Leadership
    • Board of Directors
    • Investors and Partners
  • Pipeline
    • Cefepime-Taniborbactam
    • Ceftibuten / VNRX-7145
    • PBP Inhibitor
    • VNRX-9945
  • Publications
    • Manuscripts
    • Posters
  • News & Events
    • Press Releases
    • In the News
    • Events
  • Careers
    • Open Positions
    • #venatorxcares
  • Contact
Publications
  • Publications
  • Manuscripts
  • Posters

Manuscripts

Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor
Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes
MORE MANUSCRIPTS

Posters

Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of chronic hepatitis B virus (HBV) infection
Rescue of Ceftibuten Activity by the Oral Beta-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D Beta-Lactamases.
Evaluation of the in vitro activity of cefepime plus taniborbactam (formerly VNRX-5133) and comparative agents against carbapenem-resistant Enterobacteriaceae.
MORE POSTERS
  • ©2022 Venatorx Pharmaceuticals, Inc.
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
  • Sitemap
You are using a browser that is not supported. Please consider changing your browser